Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Brain networks in Huntington disease.

Eidelberg D, Surmeier DJ.

J Clin Invest. 2011 Feb;121(2):484-92. doi: 10.1172/JCI45646. Epub 2011 Feb 1. Review.

2.

Presynaptic dysfunction in Huntington's disease.

Rozas JL, Gómez-Sánchez L, Tomás-Zapico C, Lucas JJ, Fernández-Chacón R.

Biochem Soc Trans. 2010 Apr;38(2):488-92. doi: 10.1042/BST0380488. Review.

PMID:
20298208
3.

Huntington's disease: From molecular basis to therapeutic advances.

Krobitsch S, Kazantsev AG.

Int J Biochem Cell Biol. 2011 Jan;43(1):20-4. doi: 10.1016/j.biocel.2010.10.014. Epub 2010 Nov 4. Review.

PMID:
21056115
4.

Functional interactions within striatal microcircuit in animal models of Huntington's disease.

Ghiglieri V, Bagetta V, Calabresi P, Picconi B.

Neuroscience. 2012 Jun 1;211:165-84. doi: 10.1016/j.neuroscience.2011.06.075. Epub 2011 Jul 1. Review.

PMID:
21756979
5.

The selective vulnerability of nerve cells in Huntington's disease.

Sieradzan KA, Mann DM.

Neuropathol Appl Neurobiol. 2001 Feb;27(1):1-21. Review.

PMID:
11298997
6.

Selective degeneration in YAC mouse models of Huntington disease.

Van Raamsdonk JM, Warby SC, Hayden MR.

Brain Res Bull. 2007 Apr 30;72(2-3):124-31. Epub 2006 Nov 16. Review.

PMID:
17352936
7.

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Munoz-Sanjuan I, Bates GP.

J Clin Invest. 2011 Feb;121(2):476-83. doi: 10.1172/JCI45364. Epub 2011 Feb 1. Review.

8.

Dopamine and glutamate in Huntington's disease: A balancing act.

André VM, Cepeda C, Levine MS.

CNS Neurosci Ther. 2010 Jun;16(3):163-78. doi: 10.1111/j.1755-5949.2010.00134.x. Epub 2010 Apr 8. Review.

9.

Energy deficit in Huntington disease: why it matters.

Mochel F, Haller RG.

J Clin Invest. 2011 Feb;121(2):493-9. doi: 10.1172/JCI45691. Epub 2011 Feb 1. Review.

10.

The impairment of cholesterol metabolism in Huntington disease.

Leoni V, Caccia C.

Biochim Biophys Acta. 2015 Aug;1851(8):1095-105. doi: 10.1016/j.bbalip.2014.12.018. Epub 2015 Jan 14. Review.

PMID:
25596342
11.

Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.

Giralt A, Saavedra A, Alberch J, Pérez-Navarro E.

J Huntingtons Dis. 2012;1(2):155-73. doi: 10.3233/JHD-120023. Review.

PMID:
25063329
12.

Synaptic dysfunction in Huntington's disease: a new perspective.

Smith R, Brundin P, Li JY.

Cell Mol Life Sci. 2005 Sep;62(17):1901-12. Review.

PMID:
15968465
13.

N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.

Fan MM, Raymond LA.

Prog Neurobiol. 2007 Apr;81(5-6):272-93. Epub 2006 Dec 22. Review.

PMID:
17188796
14.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

15.

The early cellular pathology of Huntington's disease.

Li XJ.

Mol Neurobiol. 1999 Oct-Dec;20(2-3):111-24. Review.

PMID:
10966117
16.

[Huntington's disease: cellular and molecular basis of pathology].

Korzhova VV, Artamonov DN, Vlasova OL, Bezprozvannyĭ IB.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2014 Jul-Aug;64(4):359-75. Review. Russian.

PMID:
25723022
17.

Rodent genetic models of Huntington disease.

Heng MY, Detloff PJ, Albin RL.

Neurobiol Dis. 2008 Oct;32(1):1-9. doi: 10.1016/j.nbd.2008.06.005. Epub 2008 Jun 26. Review.

PMID:
18638556
18.

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS.

Neuroscience. 2011 Dec 15;198:252-73. doi: 10.1016/j.neuroscience.2011.08.052. Epub 2011 Aug 27. Review.

19.

Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.

Goldberg EM, Coulter DA.

Nat Rev Neurosci. 2013 May;14(5):337-49. doi: 10.1038/nrn3482. Epub 2013 Apr 18. Review.

Supplemental Content

Support Center